The latest Investing Matters Podcast episode with multi-award-winning fund manager and international bestselling author Lee Freeman-Shor has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 604.50
Bid: 606.00
Ask: 606.50
Change: 2.50 (0.42%)
Spread: 0.50 (0.083%)
Open: 604.00
High: 608.00
Low: 600.00
Prev. Close: 602.00
TATE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

6 Feb 2020 07:00

RNS Number : 1192C
Tate & Lyle PLC
06 February 2020
 

6 February 2020 - Tate & Lyle PLC

 

TRADING STATEMENT

 

Tate & Lyle issues the following trading statement for the three months ended 31 December 2019.

 

Group

 

The underlying performance of the Group was consistent with the first half and in line with our expectations. Our guidance for the year ending 31 March 2020 remains unchanged.

 

Food & Beverage Solutions

 

Adjusted operating profit performance in the quarter continued to be strong. Sales in all regions were ahead of the comparative period as we continued to drive good price and mix management, with volume overall broadly in line. While sales growth was slower in Asia Pacific and Latin America, we saw solid growth in North America and Europe, Middle East and Africa.

 

Sucralose

 

As expected, sales and adjusted operating profit were ahead of the comparative period reflecting good operational performance and the phasing of shipments from the first half into the quarter.

 

Primary Products

 

The division remains on track to deliver steady performance in the full year. In Sweeteners and Starches, profit was higher than the comparative period with strong performance in manufacturing and supply chain and good cost discipline more than offsetting lower sweetener demand from joint ventures and continued industrial starch softness. In Commodities, profit was ahead of the comparative period due to the earlier phasing of annual contracts.

 

The 2020 calendar year bulk sweetener pricing round is nearing completion with margins broadly in line with the prior year.

 

Guidance

 

Our guidance for the year ending 31 March 2020 remains unchanged and we continue to expect earnings per share growth in constant currency to be broadly flat to low-single digit.

 

END

 

 

 

A conference call will be held today at 08.00am GMT, hosted by Nick Hampton, Chief Executive and Imran Nawaz, Chief Financial Officer. Participants are requested to dial in at least 10 minutes before the commencement of the call. Dial in details are as follows:

Standard International Access: +44 (0) 20 3003 2666

Password: Tate & Lyle

 

A replay of this call will be available after the end of the live call for 14 days until 20 February 2020.

UK replay number: 0208 196 1998

Replay access PIN: 3146870

 

For more information contact Tate & Lyle PLC:

Christopher Marsh, VP, Investor Relations

Tel: +44 (0) 20 7257 2110 or Mobile: +44 (0) 7796 192 688

 

Nick Hasell (FTI Consulting), Media Relations

Tel: +44 (0)20 3727 1234 or Mobile: +44 (0)7825 523 383

 

About Tate & Lyle:

Tate & Lyle is a global provider of solutions and ingredients for food, beverage and industrial markets.

Tate & Lyle operates through two global divisions, Food & Beverage Solutions and Primary Products, supported by the Innovation and Commercial Development and Global Operations teams. Food & Beverage Solutions is focused on growth by building leading positions globally in the categories of beverages, dairy, and soups, sauces and dressings. Primary Products is focused on delivering steady earnings and generating cash.

Food & Beverage Solutions consists of: Texturants, including speciality starches; Sweeteners, including low- and no-calorie sweeteners; and a Health and Wellness portfolio comprising mainly speciality fibres; and Stabilisers and Functional Systems, which are bespoke ingredient blends that ensure foods retain their structure.

Primary Products consists of high-volume sweeteners, industrial starches and fermentation products (primarily acidulants). It also sells co-products from the corn milling process as animal nutrition.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2019, Tate & Lyle sales totalled £2.8 billion. For more information, please visit http://www.tateandlyle.com or follow Tate & Lyle on Twitter or LinkedIn.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTKKPBDOBKDQBK
Date   Source Headline
25th May 20237:00 amRNSFinal Results
18th May 20239:30 amRNSDirector Declaration
2nd May 20232:30 pmRNSTotal Voting Rights
4th Apr 202311:00 amRNSOperating Segment Restatement
3rd Apr 20234:15 pmRNSTotal Voting Rights
8th Mar 20232:30 pmRNSDirector/PDMR Shareholding
8th Feb 20237:00 amRNSCapital Markets Event
26th Jan 20237:00 amRNSTrading Statement
6th Jan 20232:00 pmRNSDirector/PDMR Shareholding
3rd Jan 20233:17 pmRNSBlock listing Interim Review
8th Dec 20221:00 pmRNSDirector/PDMR Shareholding
30th Nov 20222:00 pmRNSHolding(s) in Company
10th Nov 20227:00 amRNSHalf-year Report
1st Nov 20223:15 pmRNSTotal Voting Rights
4th Oct 20228:25 amRNSCancellation of Preference Share Listing
3rd Oct 20222:45 pmRNSPref. share reduction effective & timetable update
29th Sep 20221:00 pmRNSTimetable update re. cancellation of pref. shares
14th Sep 202212:15 pmRNSHolding(s) in Company
13th Sep 20223:00 pmRNSCourt approval of cancellation of Pref. shares
10th Aug 20222:15 pmRNSDirector/PDMR Shareholding
4th Aug 20223:00 pmRNSDirector/PDMR Shareholding
2nd Aug 20224:00 pmRNSHolding(s) in Company
28th Jul 20221:00 pmRNSUpdate on Preference Share Reduction Timetable
28th Jul 202212:45 pmRNSResult of AGM
15th Jul 20225:20 pmRNSDirector/PDMR Shareholding
1st Jul 202210:45 amRNSBlock listing Interim Review
1st Jul 202210:17 amRNSTotal Voting Rights
29th Jun 20224:25 pmRNSDirector/PDMR Shareholding
29th Jun 20224:00 pmRNSDirector/PDMR Shareholding
24th Jun 20224:15 pmRNSHolding(s) in Company
23rd Jun 20223:00 pmRNSHolding(s) in Company
21st Jun 20222:30 pmRNSAnnual Financial Report and Notice of Meeting 2022
17th Jun 20222:00 pmRNSHolding(s) in Company
15th Jun 20222:00 pmRNSHolding(s) in Company
15th Jun 20227:00 amRNSProposed Cancellation&Repayment Preference Shares
10th Jun 20222:00 pmRNSHolding(s) in Company
9th Jun 20227:06 amRNSAcquisition
9th Jun 20227:00 amRNSFinal Results
19th May 20225:00 pmRNSDirector/PDMR Shareholding
9th May 20222:23 pmRNSHolding(s) in Company
6th May 20222:46 pmRNSHolding(s) in Company
3rd May 20225:45 pmRNSHolding(s) in Company
3rd May 20228:01 amRNSShare Consolidation Effective Total Voting Rights
29th Apr 20223:15 pmRNSListing and Trading Application
26th Apr 20224:00 pmRNSResult of Meeting
13th Apr 20222:00 pmRNSHolding(s) in Company
7th Apr 20225:30 pmRNSHolding(s) in Company
7th Apr 202211:00 amRNSCirc re. special dividend and share consolidation
5th Apr 20224:00 pmRNSHolding(s) in Company
4th Apr 20224:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.